You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Letter
Acute hepatitis C in HIV-negative men who have sex with men in the Netherlands and Belgium: a call for action
  1. Anne Boerekamps1,
  2. Kristien Wouters2,
  3. Heidi S M Ammerlaan3,
  4. Hannelore M Götz4,5,
  5. Marie Laga6,
  6. Bart J A Rijnders1
  1. 1 Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
  2. 2 Department of Clinical Sciences, Institute of Tropical Medicine, Antwerpen, Belgium
  3. 3 Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands
  4. 4 Department of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, The Netherlands
  5. 5 Department of Public Health, Erasmus MC—University Medical Center Rotterdam, Rotterdam, The Netherlands
  6. 6 Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
  1. Correspondence to Anne Boerekamps, Department of Internal Medicine and Infectious Diseases, Erasmus MC, 3000 CA Rotterdam, The Netherlands; a.boerekamps{at}erasmusmc.nl

https://doi.org/10.1136/sextrans-2018-053526

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The evidence that HIV treatment as prevention (TaSP) and HIV pre-exposure prophylaxis (PrEP) reduce the risk of HIV transmission is overwhelming. The logical consequence of both interventions is that sexual mixing between HIV-positive and negative men who have sex with men (MSM) will increase. Hepatitis C (HCV) can be sexually transmitted in MSM and until recently was thought to be limited to HIV-infected MSM.

    However, from January 2016 to July 2017, through the Dutch Acute HCV in HIV Study (a Dutch-Belgian prospective multicentre study on the treatment of acute HCV, NCT02600325) and the Be-PrEP-ared study (a PrEP project in Antwerp, Eudra CT2015-000054-37), 10 …

    View Full Text

    Footnotes

    • Handling editor Jackie A Cassell

    • Contributors AB and BJAR: study concept and design, acquisition of data, statistical analysis, analysis and interpretation of data, drafting of the manuscript, and finalising the article. KW and ML: acquisition of data, analysis and interpretation of data, critical revision of the manuscript for important intellectual content, and approval of the final article. HSMA: acquisition of data and approval of the final article. HMG: acquisition of data, critical revision of the manuscript for important intellectual content, and approval of the final article.

    • Competing interests BJAR has received a research grant from Merck Sharp & Dohme (ongoing, 2014–2017) within the context of this article. Outside the context of this article he has received research grants from Gilead Sciences (ongoing, 2013–2017), has been an investigator of trials sponsored by Merck Sharp & Dohme, Gilead Sciences and Janssen-Cilag, has been an invited speaker for Gilead Sciences, Merck Sharp & Dohme, Pfizer and Janssen-Cilag, has participated on advisory boards and has received conference invitations for Bristol-Myers Squibb, AbbVie, Merck Sharp & Dohme, Gilead Sciences and Janssen-Cilag, and has been a consultant to GL Pharmaceuticals.

    • Ethics approval DAHHS study: MEC-2015-643.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Data sharing statement If additional data are needed by medical professionals or policymakers, the first author can be contacted at a.boerekamps@erasmusmc.nl.